Uterine Fibroid Embolization (UFE): Minimally Invasive Treatment for Fibroids — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Uterine Fibroid Embolization (UFE), also called <strong>Uterine Artery Embolization (UAE)</strong>, is a minimally invasive interventional radiology procedure that treats symptomatic uterine fibroids without surgery. UFE works by selectively blocking the uterine arteries that supply blood to the fibroids, causing them to undergo ischaemic infarction — they shrink, soften, lose viability, and eventually degenerate over the following weeks and months, providing lasting relief from fibroid-related symptoms.</p><p>Uterine fibroids (leiomyomas or myomas) are the most common benign tumours in women of reproductive age, affecting up to 70–80% of women by age 50. While many fibroids are asymptomatic and require no treatment, symptomatic fibroids cause significant morbidity: <strong>heavy menstrual bleeding</strong> (menorrhagia) is the cardinal symptom, often resulting in iron-deficiency anaemia; pelvic pressure and pain; urinary frequency and urgency from bladder compression; constipation; sexual dysfunction; and, in some cases, subfertility or obstetric complications.</p><p>UFE was first described in 1995 by French interventional radiologist Hervé Tristan and gained widespread adoption through landmark trials in the late 1990s and 2000s. The EMMY trial (Netherlands), the REST trial (United Kingdom), and the FIBROID Registry (United States) together established UFE as a safe, effective, and durable alternative to hysterectomy for symptomatic fibroids, achieving similar symptom relief rates while preserving the uterus.</p><p>The procedure is performed by an interventional radiologist using fluoroscopic (real-time X-ray) guidance. Through a small (2–3 mm) puncture at the femoral artery in the groin or radial artery in the wrist, a thin flexible catheter is navigated under imaging guidance into the uterine arteries bilaterally, and tiny embolic particles (typically polyvinyl alcohol — PVA — microspheres or calibrated tris-acryl gelatin microspheres of 500–900 µm diameter) are injected to occlude the arteries supplying the fibroids.</p><p>Because the uterus receives collateral blood supply from ovarian and other pelvic vessels, normal uterine tissue recovers post-procedure while fibroid tissue — which depends predominantly on uterine artery blood flow — undergoes permanent infarction. The uterus is preserved, and the majority of patients retain normal menstrual function.</p>

<p>UFE is specifically indicated for symptomatic uterine fibroids. The procedure addresses multiple fibroid locations and subtypes, and provides relief from the diverse symptom burden that fibroids produce.</p><ul><li><strong>Heavy menstrual bleeding (menorrhagia):</strong> The most common indication and the symptom most reliably improved by UFE. Submucosal fibroids (those beneath the endometrial lining, protruding into the uterine cavity) are the principal cause of menorrhagia and respond well to UFE. Studies report a 90% rate of significant menstrual bleeding reduction at 12 months post-UFE.</li><li><strong>Pelvic pressure and bulk symptoms:</strong> Large intramural (within the uterine wall) and subserosal (projecting from the outer uterine surface) fibroids cause pelvic heaviness, pressure, and discomfort from mass effect on adjacent structures. UFE reduces fibroid volume by 50–70% at six months and up to 80–90% at two years, providing sustained relief from bulk symptoms.</li><li><strong>Urinary symptoms:</strong> Large anterior fibroids compress the bladder, causing urinary urgency, frequency, and nocturia. Posterior fibroids may compress the ureters, causing hydronephrosis. UFE-induced fibroid shrinkage relieves this compression.</li><li><strong>Iron-deficiency anaemia from fibroid-related bleeding:</strong> Chronic heavy menstrual blood loss causes iron-deficiency anaemia in a significant proportion of fibroid patients. Correction of the bleeding source through UFE allows haemoglobin and iron stores to normalise within 3–6 months post-procedure.</li><li><strong>Pelvic pain and dysmenorrhoea:</strong> Degenerating fibroids and those causing uterine distortion can produce significant dysmenorrhoea (painful periods) and chronic pelvic pain. UFE ablates these pain-generating lesions.</li><li><strong>Adenomyosis with concurrent fibroids:</strong> When fibroids coexist with adenomyosis, UFE can address both the fibroid burden and the adenomyotic component of bleeding and pain, though outcomes for pure adenomyosis are less predictable than for fibroids alone.</li></ul><p>UFE is <strong>not appropriate</strong> for: pedunculated subserosal fibroids attached by a thin stalk (risk of stalk infarction and adhesion formation), desire for future pregnancy as primary concern (fertility outcomes post-UFE are less well-studied than post-myomectomy), active pelvic infection, coagulation disorders, or known or suspected gynaecological malignancy.</p>

<p>Appropriate patient selection for UFE is critical to achieving the best outcomes and minimising complications. Selection involves a pre-procedure gynaecological consultation, MRI of the pelvis, and review by an interventional radiologist.</p><p><strong>Ideal candidates:</strong></p><ul><li>Women with symptomatic uterine fibroids (heavy bleeding, pelvic pain, bulk symptoms) confirmed on pelvic MRI</li><li>Those who wish to avoid hysterectomy and preserve their uterus</li><li>Pre-menopausal women who do not wish to retain fertility as their primary concern (though UFE is performed in women desiring future pregnancy after extensive counselling)</li><li>Women with multiple fibroids of different locations and sizes (UFE treats all fibroids simultaneously, unlike myomectomy which may miss deep intramural lesions)</li><li>Women who are poor surgical candidates due to comorbidities (obesity, diabetes, prior abdominal surgery) that increase surgical risk</li></ul><p><strong>Pre-procedural evaluation:</strong> Pelvic MRI is the preferred imaging — it precisely characterises fibroid number, size, location (FIGO classification: submucosal types 0–2, intramural types 3–4, subserosal types 5–7), vascularity, and any concurrent pathology (adenomyosis, endometrial lesions). Endometrial biopsy is performed to exclude endometrial malignancy in women with abnormal uterine bleeding. Full blood count assesses pre-procedural anaemia. Renal function (creatinine) is checked as contrast dye is used during the procedure. Pregnancy test on the day of procedure is mandatory.</p><p><strong>Contraindications:</strong> Pedunculated subserosal fibroids (type 7 — stalk diameter &lt;50% of fibroid diameter); known or suspected uterine or cervical malignancy; active pelvic inflammatory disease or endometritis; contrast allergy not controllable with pre-medication; current pregnancy; severely impaired renal function (risk from contrast nephropathy); and coagulopathy.</p><p><strong>Fertility counselling:</strong> Women who wish to conceive after UFE should have thorough counselling. Available data — including systematic reviews and cohort studies — suggest that pregnancy is possible after UFE (reported rates of 50–60% in women attempting conception), but there is a higher miscarriage rate and higher caesarean section rate compared to post-myomectomy pregnancies. Myomectomy remains the preferred option for women whose primary goal is future fertility and who have a fibroid amenable to surgical removal.</p>

<p>UFE is performed in an interventional radiology suite equipped with high-resolution fluoroscopic imaging equipment. The procedure is typically carried out under conscious sedation (intravenous midazolam and fentanyl) or, in some centres, light general anaesthesia combined with a patient-controlled analgesia (PCA) pump to manage post-procedural cramping.</p><p><strong>Step-by-step procedure:</strong></p><ul><li><strong>Arterial access:</strong> A small puncture is made in the femoral artery in the right groin (most commonly) or, increasingly, in the radial artery at the wrist (transradial approach), using a 4–5 French introducer sheath. The transradial approach reduces post-procedural access-site complications and enables same-day discharge in selected patients.</li><li><strong>Pelvic angiography:</strong> A diagnostic catheter is advanced under fluoroscopic guidance into the aorta and then into the internal iliac arteries bilaterally. Contrast injection (iodinated contrast dye) opacifies the uterine arteries and demonstrates fibroid hypervascularisation — the distinctive "tumour blush" that confirms the fibroid's blood supply.</li><li><strong>Selective catheterisation:</strong> Using a microcatheter (2.7 French) co-axially advanced through the guide catheter, the interventional radiologist selectively catheterises the uterine arteries — first one side, then the other. Super-selective catheterisation beyond any ovarian arterial branches ensures the ovarian blood supply is not compromised by the embolic particles.</li><li><strong>Embolisation:</strong> Embolic microspheres (typically PVA microspheres or Embosphere tris-acryl gelatin microspheres, 500–700 µm or 700–900 µm depending on uterine artery calibre) are injected slowly under fluoroscopic monitoring until arterial flow is reduced to near-stasis. Both uterine arteries are embolised.</li><li><strong>Completion angiography:</strong> Final angiographic imaging confirms bilateral uterine artery occlusion with preserved flow in internal iliac branches supplying other pelvic structures.</li></ul><p><strong>Technical variants:</strong></p><ul><li><strong>MRI-guided focused ultrasound (MRgFUS):</strong> A non-invasive alternative using high-intensity focused ultrasound beams directed at fibroids under MRI guidance to ablate them thermally, without any needle or catheter puncture.</li><li><strong>Radiofrequency ablation (RFA) of fibroids (Sonata/Acessa):</strong> A laparoscopic or transcervical procedure using ultrasound-guided needle placement into fibroids followed by thermal ablation with radiofrequency energy.</li></ul>

<p>UFE has been extensively studied in randomised controlled trials and large prospective registries, demonstrating a favourable benefit-to-risk profile compared to both hysterectomy and myomectomy.</p><ul><li><strong>Uterus preserved:</strong> Unlike hysterectomy, UFE preserves the uterus — critically important for women who wish to retain the possibility of future pregnancy, who have cultural or personal objections to hysterectomy, or who want to avoid the physiological changes associated with uterus removal.</li><li><strong>No surgical incision:</strong> UFE requires only a small (2–3 mm) arterial puncture. There are no abdominal incisions, no uterine incisions, and no sutures — dramatically reducing the risks of surgical adhesion formation, wound complications, and future obstetric complications from uterine scarring.</li><li><strong>Treats all fibroids simultaneously:</strong> UFE embolises all fibroids in the uterus regardless of their number, size, or location in a single procedure. Surgical myomectomy, by contrast, can miss deep intramural fibroids or very small lesions.</li><li><strong>Highly effective symptom relief:</strong> Published evidence reports 85–90% of UFE patients experience significant improvement in menstrual bleeding, 80–85% report improvement in bulk symptoms, and 70–80% report improvement in urinary symptoms. Long-term data at 5 years demonstrate durable responses in 75–80% of patients.</li><li><strong>Shorter hospital stay and recovery:</strong> UFE patients are typically observed overnight (23-hour admission) and return to normal daily activities within 1–2 weeks — significantly shorter than the 4–6 week recovery following abdominal hysterectomy or open myomectomy.</li><li><strong>Avoidance of surgical menopause:</strong> Unlike hysterectomy, UFE does not cause surgical menopause. Menstrual cycles typically resume within 2–3 cycles of UFE in pre-menopausal women.</li><li><strong>Lower transfusion rate:</strong> Blood loss during UFE is minimal (only arterial puncture blood loss), compared to the significant intraoperative blood loss risk of myomectomy (1–5% major haemorrhage rate) or hysterectomy.</li></ul>

<p>UFE is a safe procedure with a low major complication rate. However, patients must be fully informed of both short-term and longer-term potential adverse effects.</p><ul><li><strong>Post-embolisation syndrome:</strong> The most common expected side effect, occurring in 40–60% of patients. It manifests as pelvic cramping, low-grade fever (37.5–38.5°C), malaise, nausea, and mild leucocytosis in the first 24–72 hours post-procedure — representing the systemic inflammatory response to fibroid infarction. Post-embolisation syndrome is self-limiting and managed with NSAIDs, anti-emetics, and oral or intravenous hydration. It should not be confused with infection.</li><li><strong>Non-target embolisation:</strong> If embolic particles reach arteries supplying normal structures — ovaries, fallopian tubes, or adjacent pelvic organs — unintended ischaemia can occur. With current super-selective microcatheter technique, non-target embolisation is rare (&lt;1%) when performed by experienced interventional radiologists.</li><li><strong>Premature ovarian failure (POF):</strong> The most significant long-term risk, particularly for women over 40. Partial occlusion of ovarian arterial supply during UFE may accelerate ovarian aging, potentially inducing premature menopause. Reported rates of POF after UFE range from 1–3% in women under 40 to 7–14% in women 45–50. Women planning future conception or near the perimenopausal transition should be specifically counselled about this risk.</li><li><strong>Expulsion of submucosal fibroids:</strong> Submucosal fibroids that have undergone UFE-induced infarction may spontaneously expel transvaginally over weeks to months as the uterus contracts to expel the necrotic fibroid. While this represents successful treatment (the fibroid is eliminated), expulsion may be accompanied by heavy bleeding or passage of tissue requiring medical management or hysteroscopic assistance.</li><li><strong>Infection (endometritis, sepsis):</strong> Rare but serious. Infarction of large fibroid volume can theoretically create a nidus for infection. Prophylactic antibiotics are administered peri-procedurally. Signs of infection (persistent fever &gt;48 hours, purulent vaginal discharge, rising CRP) require prompt investigation and treatment.</li><li><strong>Access site complications:</strong> Femoral artery puncture site haematoma (2–3%), pseudoaneurysm (&lt;0.5%), or retroperitoneal haematoma are uncommon. Transradial access significantly reduces access-site complication rates.</li><li><strong>Contrast nephropathy:</strong> Iodinated contrast dye used during the procedure carries a risk of acute kidney injury in patients with pre-existing renal impairment. Adequate pre-hydration and using the minimum effective contrast volume mitigate this risk.</li><li><strong>Treatment failure and re-intervention:</strong> Approximately 15–25% of UFE patients require re-intervention within 5 years — either repeat embolisation for fibroid re-growth, hysteroscopic resection of an expulsing fibroid, or hysterectomy for inadequate symptom control. Risk is higher in women with predominantly submucosal fibroids or very large fibroid burden.</li></ul>

<p>Recovery from UFE is substantially faster than from surgical fibroid treatments. Understanding the expected post-procedural timeline helps patients plan appropriately and identify any deviations that warrant medical attention.</p><p><strong>Day of procedure to 48 hours:</strong> Patients are admitted for overnight observation. Pelvic cramping — ranging from mild to severe — is the predominant symptom in the first 24 hours as the fibroids undergo infarction. An analgesic regimen combining scheduled NSAIDs (ibuprofen 400–800 mg every 6–8 hours), paracetamol, and a short course of oral opioids (tramadol or codeine) is standard for the first 48–72 hours. Post-embolisation fever and malaise are managed with antipyretics and hydration. Patients are discharged home the morning after the procedure with a 5–7 day oral analgesic and anti-nausea prescription.</p><p><strong>Week 1–2:</strong> Mild to moderate cramping, fatigue, and light vaginal spotting are normal. Most patients are able to perform light household activities within 3–5 days. Desk workers typically return to work by days 7–10. Driving is not recommended for the first week. Strenuous exercise, heavy lifting, and sexual intercourse are restricted for 2 weeks.</p><p><strong>Weeks 2–6:</strong> Progressive improvement in energy and reduction in pelvic discomfort. The first post-UFE menstrual cycle (usually occurring 4–6 weeks post-procedure) is typically heavier and more crampy than normal — this is expected and does not indicate treatment failure. Improvement in menstrual flow typically becomes apparent from the second post-UFE cycle.</p><p><strong>3–6 months post-UFE:</strong> Pelvic MRI is performed to objectively document fibroid shrinkage and necrosis. Expected findings include 50–70% reduction in fibroid volume, loss of fibroid enhancement on contrast MRI (confirming infarction), and reduction in overall uterine size. Clinical review with symptom reassessment (menstrual blood loss diary, pelvic pain scores, quality-of-life questionnaire) evaluates response.</p><p><strong>Annual follow-up:</strong> Yearly gynaecological review including pelvic ultrasound monitors for fibroid re-growth or new fibroid development. Women planning pregnancy after UFE are counselled to wait a minimum of 6–12 months post-procedure before attempting conception, and are monitored as high-risk obstetric patients.</p>

<p>UFE costs vary considerably between countries and healthcare systems. For patients who need to self-pay or are considering medical tourism, understanding the components and international variation in UFE pricing is essential.</p><p><strong>United States:</strong> UFE is among the more expensive interventional radiology procedures in the US market. Total costs — including interventional radiologist fees, anaesthesia, interventional suite facility fees, embolic agents, contrast, overnight hospital stay, and immediate post-procedural care — typically range from USD 10,000–25,000. Insurance coverage for UFE is widely available in the US (Medicare and most major commercial insurers cover UFE for symptomatic fibroids), but out-of-pocket costs can still be substantial for patients with high deductible plans.</p><p><strong>United Kingdom:</strong> On the NHS, UFE is available at designated interventional radiology centres, often with waiting times of several months. Privately, UFE costs GBP 5,000–12,000 depending on the hospital.</p><p><strong>India:</strong> UFE is available at major tertiary hospitals and interventional radiology centres in India at a total cost of approximately USD 2,000–5,000, including hospitalisation and all procedural costs. JCI-accredited and NABH-accredited hospitals in cities like Mumbai, Delhi, Bangalore, Hyderabad, and Chennai perform UFE with equivalent technical standards.</p><p><strong>Thailand:</strong> USD 4,000–8,000 at Bangkok's internationally accredited hospitals (Bumrungrad, Bangkok Hospital).</p><p><strong>Turkey:</strong> USD 3,000–7,000 at major interventional radiology centres in Istanbul.</p><p><strong>Factors affecting cost:</strong> The type and quantity of embolic agent used (PVA microspheres vs calibrated microspheres — the latter are more expensive), the complexity of the fibroid anatomy (requiring additional catheter time and contrast), the use of transradial vs transfemoral access, whether a pre-procedure MRI or post-procedure MRI is included in the package, and the overnight hospital stay costs.</p><p><strong>Comparison with alternatives:</strong> UFE is generally more cost-effective than hysterectomy (USD 15,000–30,000 in the US) or abdominal myomectomy (USD 12,000–25,000) when total costs including longer hospital stay and recovery are factored in. Over a lifetime, UFE's re-intervention rate of 15–25% must be weighed in long-term cost-effectiveness analyses.</p>

<p>A range of medical, surgical, and minimally invasive alternatives exist for symptomatic uterine fibroids. The optimal choice depends on fibroid characteristics (size, number, location), symptom severity, desire for future fertility, patient age, comorbidities, and patient preference.</p><ul><li><strong>Medical management:</strong> Hormonal medications can manage fibroid symptoms temporarily but do not permanently remove fibroids. Options include: combined oral contraceptive pills (reduce menstrual blood loss by 40–50%), levonorgestrel IUS (Mirena — reduces menorrhagia by 75–90% and is the most effective medical option for heavy bleeding), GnRH agonists (leuprorelin, goserelin — shrink fibroids by 35–65% over 3–6 months through oestrogen suppression, but fibroids regrow after cessation), GnRH antagonists (elagolix/relugolix — newer oral daily agents producing rapid, reversible oestrogen suppression), and tranexamic acid (reduces menstrual blood loss by 50% without hormonal effects).</li><li><strong>Myomectomy:</strong> Surgical removal of individual fibroids while preserving the uterus. Can be performed hysteroscopically (for submucosal fibroids: types 0–1–2), laparoscopically (for small intramural or subserosal fibroids), or via open abdominal incision (for large, multiple, or deep fibroids). Myomectomy is the preferred option for women who want to maximise future fertility potential. Fibroid recurrence after myomectomy occurs in 20–50% at 5 years.</li><li><strong>Hysterectomy:</strong> Surgical removal of the uterus — the only definitive cure for fibroids. No risk of fibroid recurrence. Appropriate for women who have completed childbearing and have severe symptoms or have failed other treatments. Can be performed abdominally, vaginally, laparoscopically, or robotically depending on uterine size and patient factors.</li><li><strong>MRI-guided focused ultrasound (MRgFUS / Exablate):</strong> A completely non-invasive outpatient procedure that thermally ablates fibroids using high-intensity focused ultrasound beams guided by real-time MRI. No incision, no radiation, no hospital stay. Currently limited by high equipment cost, long procedure times, and strict patient eligibility criteria (fibroid accessibility, absence of bowel loops in the beam path). Approved by the FDA (2004) and available at specialist centres.</li><li><strong>Radiofrequency ablation (RFA) of fibroids (Acessa / Sonata):</strong> A minimally invasive procedure (laparoscopic Acessa or transcervical intrauterine Sonata) using ultrasound-guided needle placement into fibroids followed by thermal ablation. Avoids hysterectomy and preserves the uterus. Available at select centres. Fertility outcomes post-RFA are being studied.</li><li><strong>Endometrial ablation:</strong> Appropriate for women primarily troubled by heavy menstrual bleeding who do not wish future pregnancy and do not have large fibroids. Destroys the endometrial lining to reduce or eliminate menstrual flow. Not recommended in the presence of significant intramural or submucosal fibroids that distort the uterine cavity.</li></ul><p>The decision between UFE and its alternatives should be made through shared decision-making between the patient, her gynaecologist, and the interventional radiologist, with full consideration of the patient's reproductive goals, fibroid characteristics, and preference for intervention type.</p>